Adicet Bio Inc ACET Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Orbimed Advisors Llc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,041,700

Price:

$2.40
Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Orbimed Advisors Llc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

242,200

Price:

$2.40
Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Orbimed Advisors Llc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,841,100

Price:

$2.40
Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Gordon Carl L

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,041,700

Price:

$2.40
Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Gordon Carl L

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

242,200

Price:

$2.40
Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Gordon Carl L

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,841,100

Price:

$2.40
Jan 24, 2024 (filed on Jan 26, 2024)

Insider Name:

Galimi Francesco

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

288,134

Price:

--
Jan 24, 2024 (filed on Jan 26, 2024)

Insider Name:

Galimi Francesco

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

26,300

Price:

--
Jan 24, 2024 (filed on Jan 26, 2024)

Insider Name:

Galimi Francesco

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,957

Price:

$2.40
Jan 24, 2024 (filed on Jan 26, 2024)

Insider Name:

Aftab Blake

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

241,173

Price:

--

Filings by filing date

Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Orbimed Advisors Llc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,041,700

Price:

$2.40
Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Orbimed Advisors Llc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

242,200

Price:

$2.40
Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Orbimed Advisors Llc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,841,100

Price:

$2.40
Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Gordon Carl L

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,041,700

Price:

$2.40
Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Gordon Carl L

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

242,200

Price:

$2.40
Jan 25, 2024 (filed on Jan 26, 2024)

Insider Name:

Gordon Carl L

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,841,100

Price:

$2.40
Jan 24, 2024 (filed on Jan 26, 2024)

Insider Name:

Galimi Francesco

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

288,134

Price:

--
Jan 24, 2024 (filed on Jan 26, 2024)

Insider Name:

Galimi Francesco

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

26,300

Price:

--
Jan 24, 2024 (filed on Jan 26, 2024)

Insider Name:

Galimi Francesco

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,957

Price:

$2.40
Jan 24, 2024 (filed on Jan 26, 2024)

Insider Name:

Aftab Blake

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

241,173

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	200 BERKELEY STREET, 19TH FLOOR BOSTON MA 02116
Tel:	N/A
Website:	https://www.adicetbio.com
IR:	See website

Key People

Chen Schor President, Chief Executive Officer, Director	Nick Harvey Chief Financial Officer	Don G. Healey Chief Technology Officer
Blake Aftab Chief Scientific Officer	Francesco Galimi Chief Medical Officer

Business Overview

Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

Financial Overview

For the fiscal year ended 31 December 2023, Adicet Bio Inc revenues decreased from $25M to $0K. Net loss increased from $69.8M to $142.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 51% to $96.9M (expense), Stock-based Compensation in R&D increase of 27% to $9.1M (expense).

Employees:	143 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$6.65M as of Dec 31, 2023
Annual revenue (TTM):	$0.00M as of Dec 31, 2023
EBITDA (TTM):	-$126.42M as of Dec 31, 2023
Net annual income (TTM):	-$142.66M as of Dec 31, 2023
Free cash flow (TTM):	-$98.18M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	82,153,984 as of Mar 14, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization